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Mucins are high molecular weight glycoproteins expressed on the apical surface of normal epithelial cells. In cancer disease mucins are
overexpressed on the entire cellular surface. Overexpression of MUC1 mucin in pancreatic tumours has been correlated with poor
patient survival. Current chemotherapeutic approaches such as 5-fluorouracil (5-FU) has produced limited clinical success. In this
study we investigated the role of mucin in cytotoxic drug treatment to determine whether the extracellular domain of mucin impedes
cytotoxic drug action of 5-FU. Human pancreatic cancer cells revealed high and relatively moderate MUC1 levels for Capan-1 and
HPAF-II, respectively, compared to MUC1 negative control (U-87 MG glioblastoma) that showed relatively non-specific anti-MUC1
uptake. Benzyl-a-GalNAc (O-glycosylation inhibitor) was used to reduce mucin on cell surfaces, and neuraminidase was used to
hydrolyse sialic acid at the distal end of carbohydrate chains. Benzyl-a-GalNAc had no effect on cell morphology or proliferation at
the concentrations employed. The inhibition of O-glycosylation resulted in significant 5-FU antiproliferative activity against Capan-1
and HPAF-II, but not against U-87 MG. However, the exposure of cells to neuraminidase failed to improve the cytotoxic action of
5-FU. Our experimental findings suggest that the overexpression of mucin produced by human pancreatic tumours might limit
the effectiveness of chemotherapy.
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Numerous methods have been advocated for the treatment of
human pancreatic (mucinous) carcinoma. The American Cancer
Society has reported that no single treatment satisfies all treatment
guidelines for malignant pancreatic disease, nor offers any
significant impact on patient survival (American Cancer Society,
2007). A combination of surgical and non-surgical practices may
thus be required to successfully eradicate the human disease. In
order to improve treatment approaches we must consider the
biology of pancreatic tumours at the molecular, cellular and
physiological levels.
With the exception of gemcitabine there are no compelling data
to support the use of any other drug agent (alone or in
combination) over the use of fluoropyrimidines with regard to
patient survival. Fluoropyrimidines work by inhibiting thymidy-
late synthase, a rate-limiting enzyme in de novo pyrimidine
deoxynucleotide biosynthesis (van Triest and Peters, 1999; Fish-
man and Wadler, 2001). Although 5-fluorouracil (5-FU) has
demonstrated antitumor activity, poor drug selectivity and modest
tumour response to therapy have limited overall clinical success
(Khanna et al, 2006; Kurt et al, 2006). Since metastatic disease
remains incurable, comprehensive efforts have been undertaken to
optimise fluoropyrimidine therapy. To accomplish this goal,
factors contributing to suboptimal tumour response must be
identified and investigated. For this reason, we investigate the role
of mucin in cancer chemotherapy at the cellular level.
Mucins are high molecular weight glycoproteins having
oligosaccharides attached to a protein backbone core by O-
glycosidic linkages, and are approximately 50–80% carbohydrates
in terms of total molecular mass (Gendler et al, 1991; Ruddon,
1995; Yonezawa et al, 2002). Mucin is produced in a wide range of
host tissues including the gastrointestinal tract, lungs, kidneys,
ovaries, breast and pancreas (Gendler et al, 1991; Ho et al, 1993;
Corfield et al, 2001). Under normal physiological conditions mucin
plays a protective role in epithelial tissues, functioning in the
renewal and differentiation of the epithelium and in the regulation
of cell adhesion and effector cell function (Hollingsworth and
Swanson, 2004). High-level expression of mucin is associated with
metastasis and poor clinical outcome in patients diagnosed with
pancreatic cancer (Kigure, 2006).
Analysis of normal and tumour-derived mucins revealed that
the carbohydrate chains of mucins are shorter and more sialyated
in developing tumours compared to normal tissues (Beum et al,
1999; Peracaula et al, 2005). The synthesis of mucin on the surface
of normal epithelial cells is under strict regulation, but in tumours
there is an overabundance of mucin mainly due to elevated
expression of MUC1. MUC1 is structurally unique possessing a
transmembrane domain and a larger extracellular domain made up
of tandem repeats of 20 amino acids, and a cytoplasmic tail. The
glycoprotein is present in as many as 30–100 cellular copies
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s(Lan et al, 1990), and unlike high levels of soluble mucin (ie, MUC2),
MUC1 mucin is predominately associated with the cell membrane
(Perey et al, 1992; van de Wiel-van Kemenade et al, 1993).
The increased density of mucin located at the membrane surface
produces a structural mesh capable of limiting interactions of
tumour cell epitopes in immune recognition (Jentoft, 1990; van de
Wiel-van Kemenade et al, 1993). The main focus of the following
study was to show that the formidable extracellular domain of
mucin impedes the cytotoxic activity of 5-FU against human
pancreatic cancer cells.
In this study we optimised the concentration of benzyl-2-
acetamido-2-deoxy-a-D-galactopyranoside (benzyl-a-GalNAc), a
reagent used to inhibit the synthesis of mucin O-glycosylation of
cellular models of human pancreatic cancer. We established a
relationship between the overabundance of MUC1 with general
susceptibility of cells to the effects of 5-FU. Combinations of
differential interference contract microscopy (DIC) and fluores-
cence microscopy as well as cytotoxicity and immunofluorescence
studies were used to determine the importance of mucin in
cytotoxic drug therapy.
MATERIALS AND METHODS
Materials
The chemotherapeutic agent 5-FU, sulforhodamine B (SRB),
benzyl-a-GalNAc, neuraminidase from vibro cholerae was pur-
chased from Sigma-Aldrich (St Louis, MO). TCA (trichloroacetic
acid) and 1% acetic acid was purchased from Fisher Scientific
Company (Fair Lawn, NJ). Fluorescein isothiocyanate (FITC)-
conjugated mouse anti-human CD227 (MUC1) monoclonal anti-
body was purchased from BD Pharmingen (San Jose, CA). FITC-
conjugated Maackia amurensis lectin (MAA) was purchased from
EY Laboratories, Inc (San Mateo, CA). Cell culture media Eagle’s
minimum essential medium (EMEM), and Iscove’s modified
Dulbecco’s medium and trypsin-ethylenediaminetetraacetic acid
were purchased from ATCC (Manassas, VA).
Cell culture
The human pancreatic cancer cell lines Capan-1 (HTB-79) and
HPAF-II (CRL-1997) were maintained in Iscove’s modified
Dulbecco’s Medium and EMEM, respectively. The human brain
cancer cell line U-87 MG (glioblastoma, astrocytoma grade III) was
maintained in EMEM supplemented with 10% fetal bovine serum.
All cell lines were grown in a humidified CO2 atmosphere at 371C.
Immunofluorescence staining of cells
Sterile coverslips were placed in a six-well plate (Corning, NY).
Cells were next seeded at 5 10
5 per ml in the same six-well plate.
Following an incubation period of 24h at 371C, 4ml of FITC-
conjugated mouse anti-human CD227 (MUC1) monoclonal anti-
body was added to each well. Cells were incubated for an
additional 24h with antibody and washed with 1 phosphate-
buffered saline (PBS) to remove unassociated antibody. The
coverslip from each well was mounted onto a glass microslide
(Corning, NY) with fluor mounting media (Trevigen Inc, MD)
(Lemken et al, 2007). Finally, the association of CD227 (anti-
MUC1) antibody with cells was determined using a combination of
fluorescence and DIC microscopic applications at  20 magnifica-
tion (Olympus BX61WI, Melville, NY).
Cell toxicity studies using benzyl-a-GalNAc
Cells were seeded at 1 10
4 per ml in 48-well plates. Following a
24h incubation period at 371C, cells were exposed to various
concentrations of benzyl-a-GalNAc solution prepared in cell
culture medium. After 72h of cell exposure to benzyl-a-GalNAc,
the percent of cell viability was determined using SRB assay as
discussed elsewhere (Skehan et al, 1990; Kalra and Campbell,
2006), and calculated as follows:
Percentof cellviability ¼
Fluorescenceintensityof benzyl-a-GalNActreatedcells 100
Fluorescenceintensityof non-treatedcellsðcontrolÞ
To observe the effects of benzyl-a-GalNAc exposure on cell
morphology, DIC microscopy was employed. Sterile coverslips
were placed in a six-well plate (Corning, NY). Cells were next
seeded at 1 10
4 per ml of culture medium in the six-well plate.
Following a 24h incubation period at 371C the cells were exposed
to the maximum non-toxic concentration of benzyl-a-GalNAc
solution prepared in culture medium. Following 72h of cell
exposure to benzyl-a-GalNAc, each well was washed with 1 PBS
and the coverslip from each well was mounted onto a glass
microslide with fluor mounting media. Finally, cell morphology
was observed at  20 magnification.
RNA isolation and real-time RT–PCR
Cells were seeded at 2 10
4 cells per ml of culture medium in a 24-
well plate. Following a 24h incubation period at 371C, cells were
exposed to maximum non-toxic concentration of benzyl-a-GalNAc
prepared in required growth media. Forty-eight hours following
exposure of cells to benzyl-a-GalNAc, the total RNA was extracted
from the cells using RNA-STAT-60 (TEL-TEST, Friendswood, TX)
according to the manufacturer’s instructions. The total RNA
extracted from cells was reverse transcribed to synthesise cDNA
using SuperScript first-strand synthesis kit (Invitrogen Life
Technologies, Carlsbad, CA). The total RNA was reverse tran-
scribed in a final reaction volume of 20ml, using random hexamers
for 10min at room temperature, 1h at 421C and 15min at 701C.
Real-time PCR was performed using SYBR Green master mix
(Applied Biosystems, Foster City, CA). The primer sequences
used were: MUC1 (forward) GTGCCCCCTAGCAGTACCG, MUC1
(reverse) GACGTGCCCCTACAAGTTGG (de Cremoux et al, 2000),
L32 mRNA was the internal standard with primer sequence,
AGCAACAAGAAAACCAAGCACAT and TTGACATTGTGGAC
CAGGAACT (Lukashev et al, 2006). The real-time PCR was
performed using Applied Biosystems 7300 Real-Time PCR system
(Foster City, CA).
Anti-MUC1 antibody (CD227) association studies
Cells were seeded at 2 10
4 per ml of media in a 24-well
plate. Following a 24h incubation period at 371C, cells were
exposed to the maximum non-toxic concentration of benzyl-a-
GalNAc (as shown in Figure 2A) for 24, 48 and 72h. After each
exposure time point the cells were washed with 1 PBS and 1ml
of fresh media was added to each well. The cells were now exposed
to 4ml per well of CD227 antibody. Following 24h of incubation,
cells were washed with 1 PBS to remove any unassociated
antibody. Fluorescence intensity was measured using a fluores-
cence microplate reader (Bio-Tek Instruments Inc, VT) at
excitation and emission wavelengths of 485nm and 528nm,
respectively.
Fluorescence-activated cell-sorting analysis
Cells were seeded at 2 10
4 per ml in a 24-well plate. Following a
24h incubation period at 371C, cells were exposed to the maximum
non-toxic concentration of benzyl-a-GalNAc as shown in Figure 2A.
Forty-eight hours following exposure of cells to benzyl-a-GalNAc,
the cells were next washed two times with 1 PBS and 1ml of fresh
culture medium was added to each well. Next, cells were exposed to
4ml per well of CD227 antibody. Following 24h incubation with
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unassociated antibody, and then detached from plate using 0.5ml
per well of trypsin. Finally, cells were washed with 1 PBS and
antibody association was determined by fluorescence-activated cell
sorting (FACS) analysis (BD FACSCalibur, San Jose, CA, USA).
Effect of inhibiting O-glycosylation with benzyl-a-GalNAc
on cytotoxicity of 5-FU
Cells were seeded at 1 10
4 per ml in a 48-well plate. Following a
24h incubation period at 371C, one row of cells was exposed to a
predetermined concentration of benzyl-a-GalNAc solution pre-
pared in growth medium, and another without the glycosylation
inhibitor. Following additional 48hours of incubation each row
was washed with 1 PBS and treated with 5-FU prepared in cell
growth medium. The growth inhibitory effect of 5-FU after 24h of
exposure was determined by SRB assay and percent of viable cells
was calculated as follows:
Percentof cellviability ¼
Fluorescenceintensityof cellstreatedwithdrugð5-FUÞ 100
Fluorescenceintensityof non-treatedcellsðcontrolÞ
Cell toxicity studies post-removal of benzyl-a-GalNAc
Cells were seeded at 1 10
4 per ml in 48-well plates. Following a
24h incubation period at 371C, cells were exposed to the maximum
non-toxic concentration of benzyl-a-GalNAc solution prepared in
media. Following 48h exposure to benzyl-a-GalNAc, cells were
washed with 1 PBS and then allowed to grow for an additional
24, 48 and 72h in fresh culture medium. We determined percent of
cell viability and investigated cell morphology 24 to 72h post-
removal of benzyl-a-GalNAc by SRB assay and DIC microscopy,
respectively.
Effect of neuraminidase action on cytotoxic effect of 5-FU
HPAF-II cells were seeded at 1 10
4 per ml in 48-well plates.
Following 24h incubation period at 371C, cells were exposed to
neuraminidase (0.05Uml
 1) for 1h. The removal of sialic acid
residues from cell surface was confirmed by exposing cells to
0.05Uml
 1 neuraminidase for 1h and labelled with 5ml per well
FITC-conjugated MAA lectin for 30min followed by FACS
analysis. To determine the effect of neuraminidase on CD227
association, cell exposed to neuraminidase were labelled with 4ml
per well of CD227 antibody for 4h and antibody association
determined using FACS analysis. Finally, cells exposed to
0.05Uml
 1 neuraminidase and were then treated with 5-FU
(prepared in required growth medium) for 24h. Percent cell
viability was determined by SRB assay.
Statistical analysis
To determine the significant difference between experimental
groups, nonparametric Mann–Whitney U-test was used. Statistical
significance was established at Pp0.001. Analysis was performed
using the statistical package SPSS 12.0 (SPSS Inc, Chicago, IL).
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Figure 1 Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II
cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of
FITC-conjugated anti-MUC1 antibody (CD227) associated with cells. (G, H, I) Superimposed images confirm areas of antibody location with respect to
each cellular cluster ( 20 magnification).
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sRESULTS
Immunofluorescence: relative sensitivity and selectivity of
MUC1 (CD227) antibody for human pancreatic cancer cells
MUC1 is heterogeneously expressed in various physiological
states. The structural mesh of mucin produced by cells in
mucinous carcinomas (such as breast and pancreatic cancer) has
been suggested to limit immune cell recognition by blocking the
infiltration of lymphocytes in tumour tissues (van de Wiel-van
Kemenade et al, 1993).
We investigated the role of membrane-associated mucin during
cytotoxic drug treatment. We first confirmed whether anti-MUC1
antibody (CD227) is reliable enough to report changes in antibody
binding to the peptide core whether in response to inhibition of
O-glycosylation, or shedding of glycosylated functional groups
from the core protein. We therefore evaluated the interaction of
CD227 against two mucin-expressing human pancreatic cancer cell
lines (Capan-1 and HPAF-II), and one (non-mucin expressing)
human glioblastoma (U-87 MG) cell line as a negative control.
Each cell line was incubated with FITC-conjugated CD227 and
subsequently analysed by DIC and fluorescence microscopy to
establish sensitivity and selectivity levels of CD227. DIC images
show tightly joined clusters of Capan-1 and HPAF-II cells; images
of regions surrounding individual cells were difficult to acquire
(Figure 1A and B). Figure 1C shows a uniform arrangement of
U-87 MG cells. Cells were more uniform in shape compared to
Capan-1 and HPAF-II with limited intercellular associations; no
cell clustering was observed.
Fluorescence images acquired for the interaction of CD227 with
Capan-1 cells showed areas of intense antibody association,
compared to relatively low uptake by HPAF-II and non-specific
interaction with U-87 MG (Figure 1D–F). Capan-1 and HPAF-II
cells have been shown elsewhere to produce heavy and moderate
levels of MUC1, respectively. Our antibody-cell recognition studies
involving the use of CD227 support other published reports (Sipos
et al, 2003).
CD227 accurately distinguished between high and relatively low
MUC1 mucin expression, and therefore represents a sensitive tool
to evaluate the role of MUC1 during cytotoxic drug therapy.
Relative to Capan-1 and HPAF-II, U-87 MG failed to recognise
CD227, suggesting that CD227 can be used as a selective indicator
of MUC1 positive expression for remaining studies (Figure 1G–I).
Moreover, the distribution of MUC1 was generally observed on the
entire surface of human pancreatic cells, and our CD227 reactivity
studies involving Capan-1 show MUC1 mucin on Capan-1 cell
membranes surrounding the cytoplasmic and nuclear cell com-
partment (Figure 1G).
e df
c ab
Capan-1 HPAF-II U-87 MG 
–
+
0
40
80
120
160
200
Capan-1 HPAF-II U-87 MG
M
U
C
1
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
(
r
e
l
a
t
i
v
e
 
u
n
i
t
s
)
– Benzyl--GalNAc 
+ Benzyl--GalNAc 
0
20
40
60
80
100
120
0.0 0.1 0.2 0.4 0.8 1.0 2.0
P
e
r
c
e
n
t
 
 
v
i
a
b
i
l
i
t
y
Benzyl--GalNAc (mg ml–1)
# ∗
Figure 2 Determining the maximum non-toxic concentration of benzyl-a-GalNAc. (A) Percent cell viability of Capan-1 (J), HPAF-II (’) and U-87 MG
(D) cells was determined after exposing 1 10
4 cells per ml to different concentrations of benzyl-a-GalNAc for 72h. Percent viability of Capan-1 cells was
significantly lower at concentrations greater than 0.4mgml
 1 (
#Po0.05 vs 0.8mgml
 1); whereas the viability of HPAF-II cells was significantly lower beyond
0.8mgml
 1 concentration (
*Po0.05 vs 2.0mgml
 1); no cell death was observed for U-87 MG cells upto 2.0mgml
 1 concentration. (B) Real-time RT–
PCR showed MUC1 mRNA expression levels for Capan-1 4HPAF-II 4U-87 MG. The exposure of these cells to benzyl-a-GalNAc (þ) did not induce
alteration in MUC1 mRNA expression levels when compared to cells not exposed to benzyl-a-GalNAc ( ). (C) DIC microscopy images show morphology
of cells that were not exposed to benzyl-a-GalNAc ( ) compared to structure of cells following 72h exposure to benzyl-a-GalNAc (þ) (0.4mgml
 1 for
Capan-1; 0.8mgml
 1 for HPAF-II and U-87 MG) ( 20 magnification).
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determination of maximum non-toxic concentration
O-glycosylation is required for mucin formation. The elongation of
O-glycosylated chains of the peptide core can be blocked by
culturing mucin secreting cells with benzyl-2-acetamido-2-deoxy-
a-D-galactopyranoside (benzyl-a-GalNAc) (Kuan et al, 1989).
Incubation of SUIT-2 (human pancreatic cancer cell line) with
5m M of benzyl-a- GalNAc for 72h resulted in the inhibition of
mucin O-glycosylation (Kuan et al, 1989). In order to determine
the contribution of MUC1 expression in cytotoxic drug treatment,
we first determined the maximum non-toxic concentration of
benzyl-a-GalNAc that could be used to inhibit O-glycosylation of
MUC1 without causing unwanted cellular death. Results from our
cellular toxicity studies revealed a maximum concentration of 0.4
and 0.8mgml
 1 of benzyl-a-GalNAc for the pancreatic cancer cells
Capan-1 and HPAF-II, respectively (Figure 2A). The U-87 MG non-
mucin-expressing cell line tolerated 40.8mgml
 1. We performed
real-time reverse transcription (RT)–PCR to determine whether
treatment with benzyl-a-GalNAc would affect the transcript levels
of MUC1 mRNA. Capan-1 cells showed high levels of MUC1
mRNA (106.8±43.5) as compared to HPAF-II cells (49±12.2),
whereas the levels observed for negative control cell line U-87 MG
were reported at 1.1±0.4 (Figure 2B). None of the cell lines
exposed to benzyl-a-GalNAc exhibited any significant change in
levels of MUC1 mRNA expression. We also observed morpholo-
gical structures of cells after 72h exposure to benzyl-a-GalNAc and
observed no change in cell morphology compared to controls
(Figure 2C). Based on these findings, the cell lines varied in their
ability to tolerate effects of the inhibitor, and the corresponding
non-toxic concentrations did not correlate with mucin expression
levels.
Confirming the inhibition of MUC1 O-glycosylation:
determination of alterations in anti-MUC1 antibody
association
The O-glycan chains present on MUC1 mucin can restrict access of
the peptide core to antibodies (Ho et al, 1995). In order to
determine whether the concentrations of benzyl-a-GalNAc em-
ployed are sufficient to inhibit MUC1 O-glycosylation, we observed
association of CD227 antibody with cells immediately following
exposure to the inhibitor. Our results showed that antibody
association with both Capan-1 (Figure 3A) and HPAF-II
(Figure 3B) cell lines was significantly enhanced (*Pp0.001) after
24, 48 or 72h exposure to benzyl-a-GalNAc (þ) compared to
control (benzyl-a-GalNAc ( )). Similarly, FACS analysis revealed
a shift in fluorescence peaks for pancreatic cancer cells exposed to
benzyl-a-GalNAc compared to the unexposed cell population
(Figure 3 C and D), whereas no shift in peak was observed for the
negative control cell line U-87 MG (Figure 3E). The non-toxic
concentration of benzyl-a-GalNAc was capable of inhibiting MUC1
O-glycosylation, based on the extent to which the CD227 antibody
interacted with MUC1 peptide recognition site of the protein core.
Mucin is a cellular barrier limiting chemotherapeutic
action of 5-FU against human pancreatic cancer cells
Given the rapid turnover of mucin in adenocarcinomas, inhibition
of O-glycosylation will probably occur only while cells are exposed
to effect of inhibitor. Removal of benzyl-a-GalNAc will reactivate
O-glycosylation synthesis, so the exposure of cells to 5-FU
immediately following the removal of benzyl-a-GalNAc is key to
maintaining the lowest possible levels of cellular-bound mucin. We
first demonstrated the effects of increasing benzyl-a-GalNAc
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Figure 3 Inhibition of MUC1 mucin O-glycosylation. Approximately 2 10
4 cells per ml of media were exposed to benzyl-a-GalNAc for 24, 48 and 72h
followed by 24h incubation with FITC-conjugated anti-MUC1 (CD227) monoclonal antibody (4mlwell
 1)a t3 7 1C. The relative fluorescence intensities
correlate with affinity of cells pretreated with benzyl-a-GalNAc (þ) for CD227 compared to control (benzyl-a-GalNAc ( )) cells. Fluorescence intensities
for antibody associated with (A) Capan-1 and (B) HPAF-II cells exposed to benzyl-a-GalNAc was significantly higher for 24, 48 and 72h exposure time
(
*Pp0.001) as compared to control (benzyl-a-GalNAc ( )). (C–D)Fluorescence-activated cell-sorting analysis for (C) Capan-1, (D) HPAF-II and (E)U -
87 MG when exposed to benzyl-a-GalNAc (þ) and compared to cells that were not previously exposed to benzyl-a-GalNAc. The specific peaks and lines
to which the peaks are assigned are in the insert of the panel for FACS analysis.
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 1) against
HPAF-II cells. The percent of cell viability was found to decrease
with increasing concentrations of the inhibitor and this effect
was significant (*Pp0.001) at concentrations X0.4mgml
 1 as
compared to 5-FU treatment alone (Figure 4A). The percent
viability with 5-FU treatment alone was 77±2.5% which reduced
significantly to 63±8.6% when pre-treated with the maximum
non-toxic concentration of benzyl-a-GalNAc (0.8mgml
 1).
Similar results were observed for Capan-1 cells wherein the
percent viability was 65±2% with 5-FU (80mmolml
 1) alone,
which was significantly (*Pp0.001) lowered to 54±3.6% when
exposed to benzyl-a-GalNAc (0.4mgml
 1) followed by 5-FU
treatment (Figure 4B). There was no significant difference in
percent of cell viability of our control U-87 MG cells remaining at
37% when treated with 5-FU alone (100mmolml
 1) or when
exposed to benzyl-a-GalNAc (0.8mgml
 1) prior to 5-FU treat-
ment. These results suggest that the cytotoxic effect of 5-FU
against MUC1-secreting cell lines was enhanced by inhibition
of O-glycosylation.
Effect of removing membrane-associated mucin:
time-dependent analysis
Successful elimination of the glycosylated functional groups
surrounding the MUC1 peptide core should not limit the capacity
of cells to proliferate once benzyl-a-GalNAc has been removed. A
significant change in cell’s ability to multiply and divide due to
exposure to benzyl-a-GalNAc would affect the measure of MUC1’s
role in our experiment. We next exposed Capan-1 and HPAF-II
cells to benzyl-a-GalNAc for 48h. Percent of cell viability was
determined 24, 48 and 72h after removal of benzyl-a-GalNAc. We
observed no significant effect of inhibitor on growth of Capan-1
(Figure 5A) and HPAF-II (Figure 5B) cells post-removal of benzyl-
a-GalNAc, compared to untreated controls. We next looked at DIC
images of cells post-removal of benzyl-a-GalNAc and observed no
visible morphological changes in cellular structures for both cell
lines (Figure 5C and D).
On the basis that the rate of cellular proliferation is an accurate
indicator of general cell health, our data supports the hypothesis
that the concentration of benzyl-a-GalNAc selected for pre-
treatment of Capan-1 and HPAF-II cells was non-toxic upto
several days post-removal. Under these conditions the effect of
chemotherapeutic agents (ie, 5-FU) against cells previously
exposed to benzyl-a-GalNAc must be due to the chemotherapeutic
agent alone, and not related to cellular exposure to benzyl-a-
GalNAc.
Effects of removing sialic acid residues on 5-FU
cytotoxicity
In several pancreatic cancer cells the presence of terminal sialic
acid sugar moiety on carbohydrate chains is higher due to the
overexpression of sialyltransferases (Peracaula et al, 2005). We
next determined whether the removal of the terminal sialic acid
moiety of underglycosylated mucin sufficient to improve cytotoxic
action of 5-FU, or is removal of the entire carbohydrate chain
required.
The enzyme neuraminidase was employed to cleave N-
acetylneuraminic (or sialic acid), commonly associated with
glycoproteins (Varki and Diaz, 1983). We observed that the
concentrations of neuraminidase up to 0.05Uml
 1 had no effect
on the growth of HPAF-II cells (Figure 6A). We next exposed these
cells to (0.05Uml
 1 of) neuraminidase and confirmed the cleavage
of sialic acid groups using FITC-conjugated MAA lectin, which
binds to sialic acid residues (Wang and Cummings, 1988). FACS
analysis revealed lower fluorescence intensities (shift in peak to the
left) for cells exposed to neuraminidase compared to control
without neuraminidase. Removal of sialic acid groups from
underglycosylated carbohydrate chains was achieved (Figure 6B).
We next observed that the exposure of cells to the action of
neuraminidase did not significantly improve general access of
CD227 to the MUC1 protein core (Figure 6C), and so the drug
barrier effect of mucin was functionally intact in the absence of
sialic acid. The next study explored the cytotoxic effect of 5-FU
against cells previously exposed to neuraminidase. The effect of
5-FU against cells only or cells pretreated with neuraminidase was
59.3±11.8 and 61.7±11.1%, respectively (Figure 6D). We thus
conclude that pre-treatment of cells with neuraminidase failed to
influence general susceptibility of cells to the cytotoxic effects
of 5-FU.
DISCUSSION
The effectiveness of most chemotherapeutic agents depends on
adequate intracellular uptake of drugs by tumour cells. Over-
expression of certain cell membrane proteins such as p-
glycoprotein and multidrug resistant proteins of cancer cells
has been shown to contribute towards cellular resistance to
chemotherapy by reducing intracellular drug uptake (Sharom,
1997). Several studies have identified mucins as one of the
significant components of the cell surface glycocalyx in various
tumour types such as colon, breast, lung and pancreas (Moniaux
0
20
40
60
80
100
Benzyl--GalNAc 5-FU
Benzyl--GalNAc + 5-FU
HPAF-II U-87 MG
P
e
r
c
e
n
t
 
v
i
a
b
i
l
i
t
y
Capan-1
0
20
40
60
80
100
0.2 0.8 0.4 0 0.6
Benzyl--GalNAc (mg ml–1)
P
e
r
c
e
n
t
 
v
i
a
b
i
l
i
t
y ∗
∗ ∗
∗
∗
Control 5-Fluorouracil
Figure 4 Effect of MUC1 mucin O-glycosylation on the cytotoxic action
of 5-FU. We exposed (B1 10
4) cells to benzyl-a-GalNAc for 48h
followed by 24h of treatment with 5-FU. (A) Percent viability of control
cells (exposed to benzyl-a-GalNAc alone) was approximately 100%,
whereas viability of HPAF-II cells exposed to benzyl-a-GalNAc followed by
5-FU treatment decreased with increasing concentrations of benzyl-a-
GalNAc, and was significant at concentrations X0.4mgml
 1 (
*Pp0.001 vs
5-FU treatment alone). (B) Percent viability of Capan-1 and HPAF-II cells
were significantly lower (
*Pp0.001) for cells exposed to benzyl-a-GalNAc
followed by 5-FU treatment, compared to cells treated with 5-FU alone.
The percent viability of U-87 MG cells (negative control) was similar for
cells exposed to benzyl-a-GalNAc followed by 5-FU compared to 5-FU
treatment alone.
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set al, 2004). We investigated the role of mucin in cytotoxic drug
therapy using two cellular models of human pancreatic cancer. We
selected our cell lines based on their ability to produce relative
amounts of MUC1 mucin. For example, Capan-1 and HPAF-II have
been reported to overexpress MUC1 mucin (Sipos et al, 2003); U-
87 MG is negative for MUC1 expression as determined by FACS
analysis using a multimodal imaging probe against MUC1 (Moore
et al, 2004). The expression of MUC1 in normal epithelial cells is
confined to the apical surface, but covers the entire surface of
many cancer cells. Our immunofluorescence images support this
observation: Capan-1 4HPAF-II 4U-87 MG. The overexpression
of MUC1 mucin has been shown to sterically hinder cell–cell and
cell–matrix interactions (Wesseling et al, 1996). Moreover,
the dense O-glycosylation on MUC1 can mask several cell
surface receptors shown to reduce transfection efficiency
(Stonebraker et al, 2004).
The extent to which the dense mucin mesh influences the
antiproliferative activity of 5-FU was investigated using human
pancreatic cancer cells. In several studies we used a FITC-
conjugated CD227 antibody to probe the existence of a single
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Figure 5 Cell proliferation and morphology post-removal of benzyl-a-GalNAc. (A) Capan-1 and (B) HPAF-II cells (1 10
4 cells per ml) were exposed
to 0.4 and 0.8mgml
 1 of benzyl-a-GalNAc, respectively. Following 48h exposure to benzyl-a-GalNAc the cells were washed with 1 PBS and allowed to
grow for next 24, 48 and 72h in fresh media. The percent viability of cells was measured at each time point following exposure to benzyl-a-GalNAc (open
bars, &) and compared with percent viability of cells not exposed to benzyl-a-GalNAc (closed bars, ’). (C–D) Viability of Capan-1 and HPAF-II cells at
100% 24, 48 and 72h post-removal of benzyl-a-GalNAc, and DIC microscopy of (C) Capan-1 and (D) HPAF-II cells post-removal of inhibitor ( 20
magnification).
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smucin variety, MUC1. We note that other membrane-bound
mucins such as MUC3, MUC4, MUC12, MUC16 and MUC17 are
also present (Hollingsworth and Swanson, 2004; Moniaux et al,
2004); relative contribution to the functional mucin barrier effect is
probably determined by their relative abundance and extended
extracellular domain sequence.
It was reported that relatively high concentrations of 5-FU are
required to achieve significant in vitro cytotoxic effects against
Capan-1 and HPAF-II cells (Kalra and Campbell, 2006). Herein, we
report the effect of inhibiting MUC1 O-glycosylation on the
cytotoxic activity of 5-FU. We used benzyl-a-GalNAc (inhibitor of
O-glycosylation) to reduce the mucin glycation mesh surrounding
cells. The concentrations of benzyl-a-GalNAc employed for Capan-
1 (0.4mgml
 1) and HPAF-II (0.8mgml
 1) had no effect on
normal cell proliferation. Previous reports have shown that
morphological changes in cells can result from exposure to
benzyl-a-GalNAc. For example, Ls174T cells showed formation of
intracellular cysts when exposed to benzyl-a-GalNAc for more
than 3 days. Similar observations were made with HT-29 cells,
which showed swelling of cells and accumulation of intracyto-
plasmic vesicles after prolonged exposure to the inhibitor
(Leteurtre et al, 2003) however, Caco-2 cells showed no
morphological changes. These studies suggested that the effect of
benzyl-a-GalNAc is actually cell line dependent (Byrd et al, 1995;
Leteurtre et al, 2003), and so concentration of inhibitor employed
should vary according to cell type.
We exposed our cells to the maximum non-toxic concentration
of benzyl-a-GalNAc for no more than 3 days. We observed no
effect on cell morphology or in rates of proliferation during
periods of cell exposure to benzyl-a-GalNAc, or days following the
post-removal of reagent. The effect of benzyl-a-GalNAc on our cell
lines was thus limited to the inhibition of mucin O-glycosylation
alone, and did not include any unwanted cytotoxic effects at the
concentrations employed. Previous reports have suggested that
benzyl-a-GalNAc treatment can alter the apical expression of
MUC1 on surface of HT-29 cells, whereas no such alteration was
seen in Capan-1 cells (Leteurtre et al, 2003). The exposure of
benzyl-a-GalNAc to cells used in this study did not induce
alterations in MUC1 transcript expression, and therefore the
exposure did not alter the overall expression of MUC1 on apical
surface of these cells.
The ability of benzyl-a-GalNAc to inhibit MUC1 O-glycosylation
has been confirmed previously using lectin labelling in HT-29
and Capan-1 cells (Leteurtre et al, 2003). The inhibition of MUC1
O-glycosylation in pancreatic cancer cells was confirmed by
alterations in CD227 antibody association following exposure to
benzyl-a-GalNAc. Both Capan-1 and HPAF-II cells showed higher
CD227 antibody association after benzyl-a-GalNAc exposure. The
concentrations of the inhibitor used was therefore sufficient to
inhibit O-glycosylation, which in turn reduced the mucin mesh
and improved the general access of CD227 to the (20 amino acid
tandem repeats of the) MUC1 protein.
In order for 5-FU to exert its cytotoxic effect, a sufficient amount
of drug must reach the intracellular compartment where 5-FU is
converted to active metabolites (Weckbecker, 1991). The role of
the mucus layer secreted on the normal intestinal epithelium in
limiting diffusion of nutrients and small molecules has been
discussed previously (Specian and Oliver, 1991). Studies outlined
here support the role of mucin during cytotoxic drug therapy. The
inhibition of mucin O-glycosylation enhanced the cytotoxic effects
of 5-FU against human pancreatic cancer cell lines, but not against
the mucin-deficient cell line. The exact mechanism is not known,
but we speculate that the inhibition of mucin glycosylation may
reduce the formidable mucin O-glycosylation mesh, facilitate the
diffusion of drugs across the compromised mucus layer, improve
intracellular drug uptake and enhance cytotoxic drug action.
Interestingly, the removal of sialic acid residue present at the
terminal end of O-linked carbohydrate chains did not improve the
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Figure 6 Effect of sialic acid removal on cytotoxic activity of 5-FU. Approximately 1 10
4 HPAF-II cells per ml of growth medium were exposed to
neuraminidase for 1h at 371C. (A) Cell viability was 100% upto 0.05Uml
 1 concentration of neuraminidase. (B) FACS analysis showing decrease in
fluorescence intensity (correlating to association of FITC-conjugated MAA lectin to the sialic acid residues) for cells exposed to (þ) neuraminidase
compared to cells without exposure to ( ) neuraminidase. (C) FACS analysis showing no change in fluorescence peaks for CD227 association with or
without neuraminidase treatment. (D) When cells were previously exposed to neuraminidase (þ), the effect of 5-FU on percent of cell viability was not
significantly different from the control (neuraminidase ( )).
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scytotoxic effect of 5-FU. The entire mucin carbohydrate chain may
thus function in reducing intracellular uptake of 5-FU. Reducing or
eliminating the functional barrier effect of mucin might provide
opportunities to improve therapy.
On the basis of our findings, we report that the overexpression of
MUC1 mucin on the surface of human pancreatic cancer cells impede
the cytotoxic activity of 5-FU. Investigations into the role of mucin
during chemotherapy in preclinical models are necessary to better
understand the clinical implications of our experimental findings.
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